News Cardiol Therapeutics Inc.

Stocks

CRDL

CA14161Y2006

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 16:00:00 2026-07-23 EDT			5-day change	1st Jan Change
1.740 ^CAD	-4.40%		0.00%	+32.82%

05-11	Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment	MT

All News

Mentions Relevance

07-14	Cardiol Therapeutics : rsquo; Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PU
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PR
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	AQ
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	PR
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	AQ
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	PR
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	AQ
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	PR
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	AQ
05-14	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PR
05-14	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	AQ
05-11	Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment	MT
05-07	Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis	MT
05-07	Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association	MT
05-07	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	PR
05-07	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	AQ
05-07	Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association	CI
04-28	Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.	MT
04-28	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	PR
04-28	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	AQ
04-28	Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx	CI
04-14	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart	NE
04-01	Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial	MT
04-01	Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis	RE